|Articles|June 29, 2018 (Updated: November 15, 2020)
Korean Biotech Talks About U.S. Company Launch
Author(s)Michelle Maskaly
Enzychem Lifesciences explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.
Advertisement
Enzychem Lifesciences’ Chairman and CEO, Ki-Young Sohn explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.
He spoke to Pharm Exec during a company event in New York City.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
2
Bringing HIV Prevention DTC: Q&A with Ashley Gildea
3
Leading in the Psychedelic Space: Q&A with Tarek Rabah
4
FDA Approves Hernexeos Under National Priority Voucher Program
5